npressfetimg-5768.png

Gilead Announces New England Journal of Medicine Publication of Data Demonstrating Veklury® (Remdesivir) Significantly Reduced Risk of Hospitalization in High-Risk Patients With COVID-19 – BioSpace

FOSTER CITY, Calif.–(BUSINESS WIRE)– Gilead Sciences, Inc.  (Nasdaq: GILD) today announced full results from a Phase 3 investigational study evaluating the efficacy and safety of a three-day course of Veklury® (remdesivir) for intravenous (IV) use for the treatment of COVID-19 in non-hospitalized patients at high risk for disease progression. The results have been published today in the New England Journal of Medicine (NEJM) and have been submitted to the Food and Drug Administration (FDA) for the potential use of Veklury in earlier stages of disease, including prior to hospitalization.

Participants receiving Veklury treatment in the randomized, double-blind, placebo-controlled trial had an 87% reduction in risk for the composite primary endpoint of COVID-19-related hospitalization or all-cause death by Day 28 and an 81% reduction in the risk for the composite secondary endpoint of COVID-19-related medical visits due to COVID-19 or all-cause death by Day 28 compared to placebo. There was no difference observed in nasopharyngeal SARS-CoV-2 viral load up to Day 7 between groups, indicating that upper respiratory viral loads do not reliably predict treatment outcomes in COVID-19. In the study, no deaths were observed in either arm by Day 28.

The study includes new subgroup analyses which showed consistent efficacy of Veklury for patients irrespective of their key risk factors for severe COVID-19. Participants with comorbidities such as diabetes, obesity, and hypertension had reduced risk of COVID-19-related hospitalization by Day 28 with Veklury treatment. Additional subgroup analyses showed among participants with cancer, chronic lung disease, and cardiovascular disease all instances of COVID-19-related hospitalization occurred in the placebo group. In a post-hoc analysis of participants who completed a baseline influenza patient reported outcome (FLU-PRO Plus) questionnaire any time prior to or on the first day of treatment, those receiving Veklury had a 92% greater probability of symptom alleviation by Day 14 compared to those receiving placebo.

“These data provide evidence that a three-day course of remdesivir could play a critical role in helping COVID-19 patients stay out of the hospital. While our hospitals are ready to assist patients in need, prevention and early intervention are preferable to reduce the risk of disease progression and allow patients not requiring oxygen to recover from home when appropriate,” said Robert L. Gottlieb, MD, PhD, Cardiologist at Baylor University Medical Center and Baylor Scott & White Research Institute, and primary author of the NEJM article. “Remdesivir is one of the tools frontline healthcare workers rely on to effectively treat hospitalized patients with COVID-19 and early antiviral therapy with remdesivir would be a natural extension of the continuum of care that begins with primary prevention efforts centered on vaccination. Antivirals, like remdesivir, are routinely administered as a combination of therapies to help target a virus at multiple steps in its replication process. With this in mind, as additional treatment options become available, short-course IV therapy could potentially be a complementary option in settings where outpatient infusions are available.”

The use of Veklury for the treatment of non-hospitalized patients in the United States with three days of dosing is investigational, and the safety and efficacy for this use and dosing duration have not been established or approved …….

Source: https://www.biospace.com/article/releases/gilead-announces-new-england-journal-of-medicine-publication-of-data-demonstrating-veklury-remdesivir-significantly-reduced-risk-of-hospitalization-in-high-risk-patients-with-covid-19/

Leave a Reply

Your email address will not be published. Required fields are marked *

Releated

npressfetimg-5820.png

[COLUMN] 4th COVID-19 shot? — – Asian Journal News

OMICRON is super-contagious and skyrocketing across the nation, while the virus continues to replicate and mutate mostly in the bodies of those more than 50 million unvaccinated people in the U.S. who are “carriers/transmitters” causing the current massive surges (almost a million last week) in COVID-19 infections, 70,000 hospitalizations, and about 1,300 deaths daily. Indeed, this is mostly the pandemic of the unvaccinated. Those with the booster must still be careful, since they still have a 5-10 percent chance of getting infected, especially with Omicron and future strains.

In spite of the more than 829,000 deaths in the U.S. from COVID-19, the government still refus…….

npressfetimg-5797.png

ZetaClear Reviews: Nail Fungus Topical Treatment Really Works or SCAM? – Inter Press Service

You could be scammed if you don’t order Zetaclear Nail Fungus online from the official website.

These products are often made in China, with low-quality ingredients and harmful chemicals.

All of us want to live a happy life without any problems. There are many issues that people come across in their lives. The most serious is the one that has a direct impact on your health. Many people have allergies. The infection can spread quickly and isn’t always predictable. ZetaClear It is important to protect such conditions from bacteria. One example is fungus infection in the nails of the legs and hands. It can be difficult to clean this area and it can cause the enti…….